This in vitro finding, which suggests that expression of mutant HTT may directly or indirectly activate PRKG2 to phosphorylate MYRF, is consistent with the in vivo evidence of the elevated PRKG2 (Fig 4E) and MYRF phosphorylation (Fig 3G) in the HD brains. The gene discussed is MYRF; the disease is Huntington disease.